Decision catalogueMethod
Platform story, asset check: separate them before you commit
Decision problem
Is this raise underwriting a product path or an unresolved platform science project?
Thesis
Platform breadth is not a substitute for asset-level evidence when the check size and financing narrative assume a product path.
Platform-plus-pipeline structures are common in cell therapy, oligonucleotides, degraders, and delivery technologies. They become decision hazards when platform language absorbs the burden of proof that belongs on the lead asset.
A clean claim map labels platform claims and asset claims separately, then asks what evidence would falsify the asset path even if the platform remains interesting. Use of proceeds should map to claim-resolving gates for the check being asked — not to open-ended platform exploration.
When management cannot state the separation, the partnership is negotiating a category bet while pricing an asset round. The Decision Sprint output puts that mismatch on the page.
Claim map
Claims a Decision Sprint memo would force onto the page
- Platform claims and asset claims are labeled and evidenced separately
- Asset path has falsifiers independent of platform attractiveness
- Use of proceeds maps to claim-resolving gates for this check size
Decision triggers
Outputs from the claim test that should change the conversation
- Asset-sized narrative resting only on platform language
- No evidence that would kill the asset path while leaving the platform intact
- Proceeds funding open-ended platform work framed as product progress
Related in the catalogue
- Method · how a Decision Sprint works
How claims are pulled from the thesis, checked against published evidence, and written for the investment call.
- Claim maps beat generic diligence checklists for seed decisions
How should a lean team test science under a short deal deadline?
- When potency and comparability decide the cell therapy raise
Is the next round buying a clinical claim, or an unresolved potency and comparability project?
- In oligonucleotide packages, delivery is often the product claim
Is the check buying a product path in the intended tissue, or unresolved delivery science?
Facing this cut on a live $1–10M package?
Scope a Decision Sprint for one opportunity under your deal deadline—claim map, risk register, management questions, and partner briefing.